Skip to main content
. 2017 Nov 17;7:15804. doi: 10.1038/s41598-017-16074-1

Figure 4.

Figure 4

Subgroup Analyses of Bladder Cancer Risk Related to Pioglitazone Use Versus Control for Patients with DM in Europe, and America plus Asia, Respectively from OB Studies. aWith T1DM excluded. bWith T1DM included.